Technologies related to NCI

Use of the TP5 Peptide for the Treatment of Cancer
Ref: E-007-2019 | Updated: Aug 1, 2019
Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy
Ref: E-195-2018 | Updated: Aug 1, 2019
Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents
Ref: E-276-2016 | Updated: Aug 1, 2019
New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity
Ref: E-231-2017 | Updated: Aug 1, 2019
BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
Ref: E-009-2010 | Updated: May 30, 2018
New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines
Ref: E-089-2010 | Updated: Mar 9, 2018
Silica-Coated Nanodiamonds for Imaging and Delivery of Therapeutic Agents
Ref: E-175-2012 | Updated: Apr 17, 2018
Detection of Novel Endocrine-Disrupting Chemicals in Water Supplies
Ref: E-269-2011 | Updated: Apr 20, 2016
T-Cell Therapy Against Patient-Specific Cancer Mutations
Ref: E-233-2014 | Updated: Aug 31, 2016
Immunocompetent Mouse Model for Tracking Cancer Progression
Ref: E-173-2010 | Updated: Jun 18, 2018
Zirconium-89 PET Imaging Agent for Cancer
Ref: E-111-2013 | Updated: Jul 19, 2018
UOK 268 Cell Line for Hereditary Leiomyomatosis and Renal Cell Carcinoma
Ref: E-254-2010 | Updated: Apr 24, 2018
Novel Fusion Proteins for HIV Vaccine
Ref: E-256-2012 | Updated: Sep 6, 2016
Assay to Screen Anti-metastatic Drugs
Ref: E-088-2013 | Updated: Jun 7, 2018
Method for Generating Pluripotent and Multipotent Cells
Ref: E-086-2012 | Updated: Apr 17, 2018
89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods
Ref: E-080-2014 | Updated: Aug 31, 2016
Improved Production of Prenylated Protein in Insect Cells
Ref: E-009-2015 | Updated: May 30, 2018
Engineered T Cells that Target Tumor-Specific Mutations
Ref: E-229-2014 | Updated: Aug 31, 2016
Mouse Model for the Preclinical Study of Metastatic Disease
Ref: E-296-2012 | Updated: Jun 7, 2018
Method and Device for Selectively Labeling RNA
Ref: E-119-2013 | Updated: Apr 18, 2018
Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer
Ref: E-191-2010 | Updated: Dec 14, 2018
Optical Microscope Software for Breast Cancer Diagnosis
Ref: E-286-2012 | Updated: Sep 30, 2016
High-throughput Assay to Identify New Cancer Drugs
Ref: E-031-2013 | Updated: May 30, 2018
Metastatic ovarian cancer mouse models and cell lines for preclinical studies
Ref: E-069-2012 | Updated: Nov 20, 2017
Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters
Ref: E-132-2011 | Updated: Apr 17, 2018
GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer
Ref: E-128-2009 | Updated: Apr 17, 2018
Mouse Xenograft Model for Mesothelioma
Ref: E-302-2009 | Updated: Mar 27, 2018
High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research
Ref: E-136-2012 | Updated: Apr 24, 2018
CD19/CD22 Dual Target Chimeric Antigen Receptors to Treat Human B-cell Malignancies
Ref: E-017-2017 | Updated: Jul 25, 2019
Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Ref: E-161-2018 | Updated: Jul 25, 2019
Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity
Ref: E-167-2017 | Updated: Jun 28, 2019
Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy
Ref: E-210-2018 | Updated: Jun 28, 2019
A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells
Ref: E-238-2017 | Updated: Jun 28, 2019
Using a Proximity Ligation Assay to Diagnose Lymphoma Subsets and Predict Patient Responses to Targeted Therapies
Ref: e-171-2017 | Updated: Jun 10, 2019
Cancer Therapies Using Engineered Monomeric Fc Molecules
Ref: E-019-2012 | Updated: May 31, 2019
High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin
Ref: E-040-2019 | Updated: May 15, 2019
High Affinity Monoclonal Antibodies Targeting Glypican-1
Ref: E-028-2019 | Updated: Apr 26, 2019
Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents
Ref: E-106-2017 | Updated: Apr 26, 2019
Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery
Ref: E-080-2018 | Updated: May 14, 2019
Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer
Ref: E-258-2016 | Updated: Jun 10, 2019
Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma
Ref: E-211-2016 | Updated: Dec 19, 2018
Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)
Ref: E-035-2013 | Updated: Dec 14, 2018
siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing
Ref: E-075-2018 | Updated: Dec 14, 2018
Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)
Ref: E-019-2017 | Updated: Dec 14, 2018
Melanoma-Associated Antigen-A (MAGE-A3/A6) -Specific Monoclonal Antibody
Ref: E-025-2017 | Updated: Dec 14, 2018
Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells
Ref: E-250-2016 | Updated: Dec 14, 2018
Treatment of Prostate Cancer Using Anti-androgen Small Molecules
Ref: E-015-2011 | Updated: Nov 27, 2018
Novel Small Molecule Antagonists Targeting Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Long Non-coding RNA (lncRNA) as Anticancer Agents
Ref: E-060-2018 | Updated: Nov 14, 2018
Novel Small Molecules that Inhibit Hepatitis B Virus Replication by Targeting Packaging of Pre-genomic RNA
Ref: E-062-2018 | Updated: Nov 14, 2018
Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Ref: E-205-2018 | Updated: Nov 8, 2018
Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression
Ref: E-237-2018 | Updated: Nov 8, 2018
Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs
Ref: E-256-2006 | Updated: Oct 23, 2018
Anti-SLAMF7 Chimeric Antigen Receptors
Ref: E-158-2018 | Updated: Oct 15, 2018
High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers
Ref: E-198-2018 | Updated: Oct 15, 2018
T-Cell Receptors Targeting Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1)
Ref: E-082-2018 | Updated: Oct 15, 2018
Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1
Ref: E-069-2016 | Updated: Oct 15, 2018
Rapid Manufacture of Retroviral Vectors Encoding Tumor-Specific T Cell Receptors for Adoptive Cell Immunotherapy
Ref: E-157-2017 | Updated: Oct 15, 2018
Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)
Ref: E-094-2018 | Updated: Oct 15, 2018
Catalytically Hyperactive Variant of Human APOBEC3G Protein
Ref: E-150-2018 | Updated: Oct 15, 2018
New Insect Sf9-ET Cell Line for Determining Baculovirus Titers
Ref: E-009-2008 | Updated: Oct 15, 2018
Methods For Treating or Preventing Inflammation and Periodontitis
Ref: E-015-2018 | Updated: Oct 12, 2018
Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer
Ref: E-229-2017 | Updated: Oct 12, 2018
Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy
Ref: E-068-2018 | Updated: Oct 12, 2018
T cell Receptors Which Recognize Mutated EGFR
Ref: E-098-2018 | Updated: Oct 12, 2018
The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof
Ref: E-244-2004 | Updated: Oct 12, 2018
Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells
Ref: E-138-2006 | Updated: Oct 12, 2018
Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine
Ref: E-169-2016 | Updated: Oct 12, 2018
Novel Combination of Chemical Entities for Lytic Activation and Therapeutic Targeting of Kaposi’s Sarcoma-associated Herpesvirus (KSHV)
Ref: E-223-2017 | Updated: Oct 4, 2018
Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus
Ref: E-287-2012 | Updated: Oct 1, 2018
Methods of analyzing virus-derived therapeutics
Ref: E-240-2015 | Updated: Dec 19, 2017
Detection of Colorectal Cancer with Two Novel Heme-Related Molecules in Human Feces
Ref: E-198-2014 | Updated: Jul 19, 2018
Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics
Ref: E-351-2013 | Updated: Nov 14, 2017
Nitroxyl (HNO) Releasing Therapeutics
Ref: E-019-2010 | Updated: Mar 29, 2018
Cancer Vaccine Composed of Oligonucleotides Conjugated to Apoptotic Tumor Cells
Ref: E-266-2009 | Updated: Mar 29, 2018
Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer
Ref: E-236-2012 | Updated: Jun 7, 2018
Non-invasive diagnostic and prognostic assay for early stage lung cancer
Ref: E-121-2013 | Updated: Dec 20, 2017
MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors
Ref: E-001-2012 | Updated: May 30, 2018
Allele Specific shRNA for Nanog, and Its Use to Treat Cancer
Ref: E-294-2010 | Updated: May 4, 2018
Gene Signature for Predicting Solid Tumors Patient Prognosis
Ref: E-024-2009 | Updated: Jul 19, 2018
Co-Transcriptional Assembly of Modified RNA Nanoparticles
Ref: E-223-2012 | Updated: Jun 7, 2018
Peptide Inhibitor for Treating Inflammatory Autoimmune Diseases and Inflammatory Cancers
Ref: E-281-2012 | Updated: Sep 6, 2016
Video Monitoring and Analysis System for Vivarium Cage Racks
Ref: E-090-2013 | Updated: Jul 19, 2018
Modulating Chemotherapeutic Cytotoxicity
Ref: E-296-2011 | Updated: Sep 6, 2016
Novel Kinase Inhibitors Targeting the PH Domain of AKT for Preventing and Treating Cancer
Ref: E-212-2009 | Updated: Sep 6, 2016
GTF2I Mutations as a Genetic Marker for Prognosis of Thymic Malignancies
Ref: E-109-2014 | Updated: Aug 31, 2016
Cancer Immunotherapy Using Virus-like Particles
Ref: E-050-2014 | Updated: Mar 26, 2018
Treating JC Polyomavirus Infection and Associated Leukoencephalopathy
Ref: E-549-2013 | Updated: Apr 23, 2018
Reporter Plasmid to Identify Cancer Stem Cells
Ref: E-141-2011 | Updated: Apr 17, 2018
Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen
Ref: E-021-2015 | Updated: Jul 19, 2018
Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers
Ref: E-001-2016 | Updated: Mar 23, 2018
Synthetic lipopeptide inhibitors of RAS oncoproteins
Ref: E-293-2010 | Updated: Aug 31, 2016
Modified griffithsin tandemers for enhanced activity and reduced viral aggregation
Ref: E-034-2013 | Updated: Mar 29, 2018
Nucleic Acid Nanoparticles for Triggering RNA Interference
Ref: E-156-2014 | Updated: Aug 31, 2016
Improved Pepper Spray for Repellency and Incapacitation
Ref: E-048-2010 | Updated: Dec 19, 2017
HIV-1 Therapeutic Inhibits Viral Entry
Ref: E-033-2013 | Updated: May 30, 2018
Therapeutic antibody-drug conjugates targeting CD56-positive cancers
Ref: E-221-2015 | Updated: May 30, 2018
Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents
Ref: E-167-2010 | Updated: Aug 31, 2016
Biomarker signature development: microRNAs for biodosimetry
Ref: E-066-2015 | Updated: Mar 6, 2017
Human Monoclonal Antibodies Against Dengue Viruses
Ref: E-273-2011 | Updated: Nov 14, 2017
Vaccines for HIV
Ref: E-087-2015 | Updated: Apr 17, 2018


Subscribe to Technologies related to NCI